세계의 당뇨병성 족부궤양 시장 규모 : 치료 유형별, 기기별, 최종사용자별, 지역별

Diabetic Foot Ulcers Market Size And Forecast

Diabetic Foot Ulcers Market size was valued at USD 1.53 Billion in 2023 and is projected to reach USD 3.1 Billion by 2030 , growing at a CAGR of 9.24% during the forecast period 2024-2031. Global Diabetic Foot Ulcers Market Market Drivers The market drivers for the Diabetic Foot Ulcers Market can be influenced by various factors. These may include: Growing Prevalence of Diabetes:

As the incidence of diabetes rises worldwide, so does the prevalence of diabetic foot ulcers. The need for therapies and management alternatives for diabetes is fueled by the growing number of people with the disease and the increased risk of complications such foot ulcers.

Aging Population:

Diabetes and its consequences, such as diabetic foot ulcers, are more common in the aging population. The number of individuals at risk of DFUs rises with population aging, which fuels market expansion.

Technological Advancements:

The management and results of treatment for diabetic foot ulcers are being improved by advances in wound care technology, such as improved dressings, negative pressure wound therapy, and bioengineered skin substitutes. Adoption of these technologies lowers the risk of amputations and improves healing rates, which propels market expansion.

Governmental Programs:

The DFU market is mostly driven by government programs focused at lowering the burden of diabetes and its comorbidities. The need for DFU therapies may rise in response to policies that emphasize diabetes education, prevention, and healthcare service accessibility.

Growing Healthcare Expenditure:

More access to diabetic foot ulcer therapies and management choices is made possible by rising healthcare spending, especially in emerging economies. The DFU market grows as more people and healthcare institutions devote resources to controlling diabetes and its consequences.

Awareness Programs:

By educating people on the value of foot care for diabetic patients, healthcare organizations, patient advocacy groups, and pharmaceutical companies can encourage early detection and treatment of foot ulcers, which will have a beneficial effect on the market. Diabetic foot ulcers can result in serious complications such infections and lower limb amputations, which can lead to significant healthcare costs and financial stress. It becomes essential to address these issues through efficient management and treatment plans, which propels the need for DFU goods and services.

Collaborative Research and Development:

New treatments and interventions for diabetic foot ulcers are being developed as a result of partnerships between pharmaceutical companies, academic institutions, and healthcare providers. These partnerships quicken the tempo of research and development, resulting in the release of novel goods and therapies and the expansion of the market.

Global Diabetic Foot Ulcers Market Restraints

Several factors can act as restraints or challenges for the Diabetic Foot Ulcers Market. These may include:

Expensive Treatment:

Diabetic foot ulcers can be costly to treat because they require ongoing medical consultations, specialist wound care products, and occasionally surgical procedures. Patients may have financial difficulties as a result, especially if their healthcare coverage is limited.

Inadequate Healthcare Infrastructure:

Many areas, particularly in poor nations, lack a sufficient healthcare infrastructure as well as qualified medical personnel with diabetes foot ulcer management training. Delays in diagnosis, insufficient care, and unfavorable patient outcomes may result from this.

Poor Patient Compliance:

Strict adherence to treatment regimens, which include wound care, glucose management, and lifestyle adjustments, is frequently necessary for the successful treatment of diabetic foot ulcers. However, adherence may be difficult for certain patients for a variety of reasons, including ignorance, financial difficulties, or psychological obstacles.

Growing Prevalence of Diabetes:

Diabetes is becoming more commonplace worldwide, which increases the risk of developing diabetic foot ulcers. This puts a heavy load on healthcare systems, making resource shortages worse and raising the need for treatments for diabetic foot ulcers.

Complications:

Lower limb amputation, gangrene, and infection are among the serious consequences that diabetic foot ulcers can lead to. These issues have a substantial negative influence on patients' quality of life in addition to raising healthcare expenses.

Regulatory Challenges:

Long and expensive regulatory approval procedures may impede the development and implementation of novel therapies for diabetic foot ulcers. Strict regulatory regulations could be a problem for businesses looking to launch novel treatments.

Competitive Environment:

A number of businesses are providing a variety of goods and treatments in the fiercely competitive diabetic foot ulcer market. Competitive pricing can reduce profit margins and pricing power, particularly for businesses offering new treatment choices.

Global Diabetic Foot Ulcers Market Segmentation Analysis

The Global Diabetic Foot Ulcers Market is Segmented on the basis of Type of Treatment, Devices, End-users, and Geography.

Diabetic Foot Ulcers Market, By Type of Treatment

• Topical Medications:
• Includes creams, ointments, and gels applied directly to the ulcer site to promote healing and prevent infection.
• Advanced Wound Care Products:
• This segment involves specialized dressings, bandages, and wound care devices designed to accelerate healing and maintain a moist wound environment.
• Biologics:
• Utilizes biological substances such as growth factors, skin substitutes, and stem cell therapy to stimulate tissue regeneration and wound closure.
• Hyperbaric Oxygen Therapy (HBOT):
• Involves administering oxygen at increased atmospheric pressure to enhance tissue oxygenation and promote healing in non-healing ulcers.

Diabetic Foot Ulcers Market, By Devices

• Pressure Relief Devices:
• Includes custom orthotics, offloading shoes, and diabetic foot braces aimed at reducing pressure on ulcer-prone areas of the foot.
• Wound Debridement Devices:
• Instruments and tools used to remove dead or infected tissue from the wound site to facilitate healing.
• Negative Pressure Wound Therapy (NPWT):
• Involves applying negative pressure to the wound bed through a vacuum system to promote healing and reduce wound size.
• Electrical Stimulation Devices:
• Utilizes electrical currents to stimulate wound healing and improve blood flow to the affected area.

Diabetic Foot Ulcers Market, By End-users

• Hospitals and Clinics:
• Facilities providing inpatient and outpatient care for diabetic foot ulcer patients, including wound care clinics and specialized diabetic foot care centers.
• Homecare Settings:
• Includes products and services tailored for home use, such as self-administered wound care kits and telemedicine consultations.
• Research and Academic Institutes:
• Institutions engaged in clinical research, development of novel therapies, and academic training related to diabetic foot ulcers.

Diabetic Foot Ulcers Market, By Geography

• North America:
• Leading region in terms of market share due to high prevalence of diabetes and advanced healthcare infrastructure.
• Europe:
• Significant market share attributed to increasing diabetic population and growing adoption of advanced wound care products.
• Asia-Pacific:
• Emerging market with rising diabetes prevalence and improving access to healthcare services driving market growth.
• Latin America:
• Increasing awareness about diabetic foot care and improving healthcare facilities contributing to market expansion.
• Middle East and Africa:
• Growing diabetic population and rising healthcare expenditure driving demand for diabetic foot ulcer treatment options.

Key Players

• The major players in the Diabetic Foot Ulcers Market are:

3M Co

• Smith & Nephew Plc
• B. Braun SE
• Molnlycke Health Care AB
• MiMedx Group Inc
• URGO MEDICAL Australia Pty Ltd
• Organogenesis Inc

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL DIABETIC FOOT ULCERS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL DIABETIC FOOT ULCERS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL DIABETIC FOOT ULCERS MARKET, BY TYPE OF TREATMENT

• 5.1 TOPICAL MEDICATIONS
• 5.2 ADVANCED WOUND CARE PRODUCTS
• 5.3 BIOLOGICS
• 5.4 HYPERBARIC OXYGEN THERAPY (HBOT)

6 GLOBAL DIABETIC FOOT ULCERS MARKET, BY DEVICES

• 6.1 PRESSURE RELIEF DEVICES
• 6.2 WOUND DEBRIDEMENT DEVICES
• 6.3 NEGATIVE PRESSURE WOUND THERAPY (NPWT)
• 6.4 ELECTRICAL STIMULATION DEVICES

7. GLOBAL DIABETIC FOOT ULCERS MARKET, BY END-USERS

• 7.1 HOSPITALS AND CLINICS
• 7.2 HOMECARE SETTINGS
• 7.3 RESEARCH AND ACADEMIC INSTITUTES

8 GLOBAL DIABETIC FOOT ULCERS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL DIABETIC FOOT ULCERS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Acelity L.P. Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 B. Braun Melsungen AG
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 BSN Medical GMBH
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Coloplast A/S
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 ConvaTec, Inc.
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Medline Industries, Inc.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Medtronic Plc.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Molnlycke Health Care AB
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Organogenesis, Inc.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Smith & Nephew Plc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 KEY DEVELOPMENTS

• 11.1 Product Launches/Developments
• 11.2 Mergers and Acquisitions
• 11.3 Business Expansions
• 11.4 Partnerships and Collaborations

12 Appendix

• 12.1 Related Research